Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Clinical Oncology

• Publication date

  2006-06-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2005.03.6491PMID 16682727
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

  2004cited by this paper
• Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

  2000cited by this paper
• Phase II study of oral topotecan in advanced non-small cell lung cancer.

  2000cited by this paper
• Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

  2000cited by this paper
• Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

  2000cited by this paper
• A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer.

  2000cited by this paper
• Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.

  1998cited by this paper
• A dilemma in analysis: issues in the serial measurement of quality of life in patients with advanced lung cancer.

  1997cited by this paper
• Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.

  1996cited by this paper
• Phase II study of topotecan in metastatic non-small-cell lung cancer.

  1994cited by this paper

• Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer

  2021cites this paper
• Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320)

  2020cites this paper
• Oral Chemotherapy for Treatment of Lung Cancer

  2020cites this paper
• Establishment and Characterization of a Topotecan Resistant Non-small Cell Lung Cancer NCI-H460/TPT10 Cell Line

  2020cites this paper
• Hair disorders in patients with cancer.

  2019cites this paper
• Lung Adenocarcinoma

  2019cites this paper
• Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?

  2019cites this paper
• Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model

  2018influential citation
• Docetaxel increases the risk of severe infections in the treatment of non-small cell lung cancer: a meta-analysis

  2018cites this paper
• Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer

  2017cites this paper
• Assessment of the External Validity of the National Comprehensive Cancer Network and European Society for Medical Oncology Guidelines for Non-Small-Cell Lung Cancer in a Population of Patients Aged 80 Years and Older.

  2017cites this paper
• Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

  2017cites this paper
• Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis

  2017cites this paper
• Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer.

  2017cites this paper
• Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study

  2017cites this paper
• Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations

  2016cites this paper
• Maintenance gemcitabine versus best supportive care following platinum-paclitaxel chemotherapy for patients with advanced nonsmall cell lung cancer

  2016cites this paper
• Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience

  2016cites this paper
• Immunotherapy for Non-Small Cell Lung Cancer - Finally a Hint of Hope.

  2016cites this paper
• Survival Analysis of Advanced Non–Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy

  2016cites this paper
• Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.

  2016cites this paper
• Industry corner: perspectives and controversies - The challenges of patient access to new medicines.

  2016cites this paper
• Relationship between progression‐free survival and overall survival in patients with advanced non‐small cell lung cancer treated with anticancer agents after first‐line treatment failure

  2015cites this paper
• Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy

  2015cites this paper
• Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose

  2015cites this paper
• Role of Topotecan in Non-Small Cell Lung Cancer: A Review of Literature

  2015influential citation
• Systematic qualitative review of randomised trials conducted in nonsmall cell lung cancer with a noninferiority or equivalence design

  2014cites this paper
• Carcinome bronchique non à petites cellules : quelle chimiothérapie de rattrapage ?

  2014cites this paper
• NCCN Guidelines Version 1.2015 Panel Members Non-Small Cell Lung Cancer

  2014cites this paper
• Second-line therapy in non-small-cell lung cancer: the DELTA between different genotypes widens.

  2014cites this paper
• Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer , 3 rd ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

  2013cites this paper
• Non-small Cell Lung Cancer

  2013cites this paper
• Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

  2013cites this paper
• Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy.

  2013cites this paper
• Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials

  2013cites this paper
• Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation

  2013cites this paper
• Hair Disorders Associated with Anticancer Agents

  2013cites this paper
• Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancer.

  2013cites this paper
• Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line.

  2012cites this paper
• [Second-line treatment of metastatic non-small cell lung carcinoma: What are the options today? What are the perspectives for tomorrow?].

  2012cites this paper
• Noninferiority Trials in Second-Line Treatments of Nonsmall Cell Lung Cancer: A Systematic Review of Literature With Meta-analysis of Phase III Randomized Clinical Trials

  2012cites this paper
• Role of HGF/MET axis in resistance of lung cancer to contemporary management.

  2012cites this paper
• Non-small cell lung cancer.

  2012cites this paper
• Statistical Issues and Recommendations for Noninferiority Trials in Oncology: A Systematic Review

  2012cites this paper
• Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland

  2012cites this paper
• Pharmacokinetic Modeling to Assess Factors Affecting the Oral Bioavailability of the Lactone and Carboxylate Forms of the Lipophilic Camptothecin Analogue AR-67 in Rats

  2012cites this paper
• Second-line therapy of non-small cell lung cancer

  2012cites this paper
• Assessment of quality of life in advanced non-small-cell lung cancer: an overview of recent randomized trials.

  2012cites this paper
• Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

  2012cites this paper
• Topoisomerase I Inhibitors: Current Use and Prospects

  2012cites this paper
• Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes

  2011cites this paper
• Topoisomerase I Inhibitors – The Camptothecins

  2011cites this paper
• Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study

  2011cites this paper
• Cancer bronchique non à petites cellules: la 2e ligne et au-delà

  2011cites this paper
• SULF2 Methylation is Prognostic for Lung Cancer Survival and Increases Sensitivity to Topoisomerase-I inhibitors via Induction of ISG15

  2011cites this paper
• Current use of Health-Related Quality of Life Outcomes in Advanced-stage Lung Cancer Clinical Trials

  2011cites this paper
• DNA-targeted drugs

  2011cites this paper
• Therapeutic uses of topotecan for thoracic malignancies

  2011cites this paper
• Lung Cancer: Targets and Therapy

  2010cites this paper
• Update on nonsmall cell lung cancer

  2010cites this paper
• Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer

  2010cites this paper
• Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis.

  2010cites this paper
• Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: a multi-center phase II study.

  2010cites this paper
• Second-line treatment for non-small-cell lung cancer: one size does not fit all.

  2010cites this paper
• Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC

  2010cites this paper
• Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy.

  2010cites this paper
• Pemetrexed for the treatment of relapsed non-small cell lung cancer

  2010cites this paper
• Treatment Advances in Locally Advanced and Metastatic Non-Small Cell Lung Cancer

  2010cites this paper
• Traitement de deuxième ligne du cancer bronchique non à petites cellules

  2010cites this paper
• Lactone-carboxylate interconversion as a determinant of the clearance and oral bioavailabilty of the lipophilic camptothecin analog AR-67

  2010influential citation
• Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms

  2010cites this paper
• NCCN Non – Small Cell Lung Cancer Clinical Practice Guidelines in Oncology

  2010cites this paper
• Maintenance Therapy in Advanced Non-small Cell Lung Cancer

  2010cites this paper
• Non-small cell lung cancer.

  2010cites this paper
• A phase 2 study of cetuximab in combination with docetaxel in chemotherapy‐refractory/resistant patients with advanced nonsmall cell lung cancer

  2009cites this paper
• Second and third line treatment in non-small cell lung cancer.

  2009cites this paper
• Second-line treatment in non-small cell lung cancer

  2009cites this paper
• Treatment of Advanced Lung Cancer

  2009cites this paper
• Reply to D. Tassinari et al

  2009cites this paper
• How Far Do You Go? Efficient Searching for Indirect Evidence

  2009cites this paper
• Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials.

  2009cites this paper
• Cancer treatments: can we find treasures at the bottom of the sea?

  2009cites this paper
• The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis

  2009cites this paper
• First- and second-line therapy for advanced nonsmall cell lung cancer

  2009cites this paper
• A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer

  2009cites this paper
• New avenues for second-line treatment of metastatic non-small-cell lung cancer

  2009cites this paper
• Gefitinib in the treatment of advanced non-small-cell lung cancer

  2009cites this paper
• Continuous Administration of Daily Low-Dose Temozolomide in Pretreated Patients with Advanced Non-Small Cell Lung Cancer: A Phase II Study

  2009cites this paper
• I am no one. No one is perfect...Therefore I am perfect.

  2009cites this paper
• Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study.

  2009cites this paper
• A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer.

  2008cites this paper
• Docetaxel as second line therapy in advanced non-small cell lung cancer-the dose and combination may matter!

  2008cites this paper
• New Horizons in Chemotherapy: Platforms for Combinations in First-Line Advanced Non-small Cell Lung Cancer

  2008cites this paper
• Second-Line Treatment of Advanced Non-small Cell Lung Cancer

  2008cites this paper
• Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer?

  2008cites this paper
• A Phase II Study of ABT-751 in Patients with Advanced Non-small Cell Lung Cancer

  2008cites this paper
• Influence of Previous Chemotherapy on the Efficacy of Subsequent Docetaxel Therapy in Advanced Non-small Cell Lung Cancer Patients

  2008cites this paper
• Le traitement de la rechute d’un cancer bronchique non à petites cellules de stade IV

  2008cites this paper
• The efficiency of single agent docetaxel in patients with platinum-refractory non-small cell lung carcinoma

  2008cites this paper
• A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer.

  2008cites this paper